Chi-Med, AstraZeneca's savolitinib helps some Tagrisso-resistant EGFR lung cancer patients

AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med and its MET inhibitor, savolitinib.